Access to anti-retroviral drugs, female in Nepal

Nepal: Access to anti-retroviral drugs, female was 83.0% in 2024. ◆ Volatile

Latest (2024)
83.0%
Change on year
up 6.4%
World rank
53rd
of 141 countries
All-time high
83.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Nepal, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 1 %2006: 2 %2007: 5 %2008: 9 %2009: 11 %2010: 15 %2011: 20 %2012: 24 %2013: 28 %2014: 32 %2015: 37 %2016: 40 %2017: 48 %2018: 53 %2019: 58 %2020: 62 %2021: 68 %2022: 73 %2023: 78 %2024: 83 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Nepal stood at 83.0%. That is the highest value across all 25 years on record.

That represents a change of up 6.4% on the previous year and up 159.4% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Nepal peaked at 83.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Nepal 53rd out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Nepal, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Nepal, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 1.0%
2006 2.0% +100.0%
2007 5.0% +150.0%
2008 9.0% +80.0%
2009 11.0% +22.2%
2010 15.0% +36.4%
2011 20.0% +33.3%
2012 24.0% +20.0%
2013 28.0% +16.7%
2014 32.0% +14.3%
2015 37.0% +15.6%
2016 40.0% +8.1%
2017 48.0% +20.0%
2018 53.0% +10.4%
2019 58.0% +9.4%
2020 62.0% +6.9%
2021 68.0% +9.7%
2022 73.0% +7.4%
2023 78.0% +6.8%
2024 83.0% +6.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.8% 0.0% 11.0% 10
2010s 35.5% 15.0% 58.0% 10
2020s 72.8% 62.0% 83.0% 5

Countries ranked near Nepal

  1. 50 Côte d'Ivoire 84.0% compare
  2. 50 Singapore 84.0% compare
  3. 50 South Africa 84.0% compare
  4. 53 Guinea 83.0% compare
  5. 53 Slovenia 83.0% compare
  6. 56 Portugal 82.0% compare

See the full ranking of 160 places →

More gender data for Nepal

All data for Nepal →

Frequently asked questions

What is access to anti-retroviral drugs, female in Nepal?
Access to anti-retroviral drugs, female in Nepal was 83.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Nepal?
The highest recorded value was 83.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Nepal?
The lowest recorded value was 0.0% in 2000.
How does Nepal rank for access to anti-retroviral drugs, female?
Nepal ranks 53rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Nepal?
Over the last ten years it is up 159.4%. The long-run trend across the full record is volatile.
Where does this Nepal data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Nepal. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/nepal/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/nepal/">Access to anti-retroviral drugs, female in Nepal</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.